- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03430180
Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder (NalGamb)
Double-blind, Placebo-controlled Randomised Study on the Efficacy of Naloxone Nasal Spray for the Treatment of Gambling Disorder
Primary objective:
*To determine whether treatment with naloxone hydrochloride nasal spray reduces gambling urge symptoms in patients with gambling disorder
The secondary objectives of the study are:
- To determine the effects of naloxone hydrochloride nasal spray on gambling severity, frequency and time, internet use, self-efficacy, quality of life, alcohol consumption, depression
- To evaluate the safety of naloxone hydrochloride nasal spray in the treatment of gambling disorder
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a 12 week, randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of naloxone hydrochloride nasal spray in gambling disorder. Anticipated number of participants are 126.
Treatment Group A: Naloxone hydrochloride 40mg/ml nasal spray Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Treatment Group B: Placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Safety parameters:
Study Subjects will be asked to report any changes in health via the daily questionnaire. This will be reviewed weekly and at each study Visit (including phone calls) and any adverse events will be documented in the eCRF. Changes in vital signs and outcome of routine blood analyses will be evaluated.
Adverse events (AEs) will be classified using a coding thesaurus (MedDRA).
Primary endpoint: Gambling symptoms (G-SAS) from Baseline to week 12. Gambling symptoms (G-SAS) from Baseline to week 12.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Uusimaa
-
Helsinki, Uusimaa, Finland, 00270
- National Institute for Health and Welfare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inclusion criteria:
The Subject must satisfy the following criteria for entry into the study:
- Aged 18 to 75 years, fluent in Finnish and able to read and understand the patient information sheet
- Provide written, informed consent prior to any study specific procedure being conducted
- Gambling problem at pre-screening (SOGS 5 or more points)
- Moderate (6-7 criteria met) or severe (8-9 criteria met) GD (DSM-5) assessed by clinical interview with Medical Doctor (MD)
- At least 4 weeks since completion of any other previous treatment for GD
- At least 8 weeks since completion of any previous treatment with naltrexone or nalmefene
- Willingness to comply with all study procedures and visit schedules
Exclusion Criteria:
- Exclusion criteria:
The Subject will be excluded from the study if any of the following applies:
- Two weeks or longer abstinence from gambling prior to randomisation
- Known allergic reactions to naloxone or excipients of IMP and placebo
- Current use of drugs (opiates, amphetamine, metamphetamine, cocaine, cannabis and benzodiazepines) (as assessed by saliva drug screen, DrugWipe-6)
- Subject is taking any prohibited medication (opioid analgesics, any medication delivered to the nose)
- Serious mental illness or severe Depression assessed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Disorders (SCID-I, DSM-5) and the Montgomery and Asberg Depression Rating Scale (MADRS) scores 24 points or more
- Clinically significant risk of suicide (Columbia-Suicide Severity Rating Scale (C-SSRC))
- Women who are pregnant or breastfeeding at screening or Baseline
- Serious kidney (P-Creatinine > 110 umol/ml) insufficiency
- The Subject/patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
- Liver cirrhosis or liver enzyme elevations, ASAT or ALAT >200 (by blood drop test),
- Active HCV infection (saliva test, OralQuick-HCV)
- The person that met the criteria of vulnerable person according to Finnish Medical Research Act No188/1999 7-10§
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile must use effective contraception (either combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects' usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide [double barrier methods]), and willing and able to continue contraception for 1 month after the last administration of IMP. Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bilateral tubal ligation at least six weeks before the screening visit. In case of oophorectomy alone, the reproductive status of the woman should have been confirmed by follow up hormone level assessment.
- Severe comorbidity (e.g., drug addiction, psychosis, diabetes)
- Experimental agents must have been discontinued at least 8 weeks prior to screening for a period equivalent to 5 half-lives of the agent (whichever is longer)
- Any diagnosed nasal conditions including abnormal nasal anatomy, nasal symptoms (i.e. blocked nose, nasal polyps etc.), or having product sprayed in to the nasal cavity prior to drug administration
- Subject with concurrent disease considered by the investigator to be clinically significant in the context of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: placebo nasal spray
Drug: placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
|
One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Other Names:
|
ACTIVE_COMPARATOR: Naloxone hydrochloride 40mg/ml nasal spray
Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
|
Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Gambling Symptom Assessment Scale (G-SAS) gambling symptom severity and change during the treatment - assessment
Time Frame: Baseline to week, 3, 6, 9 and week 12.
|
The G-SAS is a 12-item self-rated scale designed to assess gambling symptom severity and change during treatment.
The G-SAS is not a diagnostic or screening instrument.
Each 12-item scale has a score ranging from 0 - 4 (adjective anchors for 0 and 4 vary for each item).
All items ask for an average symptom based on the past 7 days.
Items 1 - 4 can be used to assess changes in craving symptoms.
Total score ranges from 0 - 48: extreme = 41 - 48, severe = 31 - 40, moderate = 21 - 30, mild = 8 - 20.
|
Baseline to week, 3, 6, 9 and week 12.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAS (gambling craving)
Time Frame: Baseline to Week 3, 6, 9 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 3,6,9,and 12 craving of gambling will be assessed.
|
Baseline to Week 3, 6, 9 and 12
|
Gambling severity (PGSI)
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 6, and 12 severity of gambling will be assessed.
|
Baseline to Week 6 and 12
|
Gambling severity (DSM-5)
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to week 6, and 12 severity of gambling will be assessed.
|
Baseline to Week 6 and 12
|
Gambling problems (NODS)
Time Frame: Baseline to Week 3, 6, 9 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 3,6,9,and 12 level of gambling problems will be assessed.
|
Baseline to Week 3, 6, 9 and 12
|
Gambling expenditure and frequency
Time Frame: Baseline to Week 12
|
daily questionnaire / telephone operated (text messages) diary (daily use of sprays, number of doses, gambling expenditure and frequency and possible adverse events) and self-administration of IMP.
|
Baseline to Week 12
|
Abstinence of gambling (GASS)
Time Frame: Baseline to Week 3, 6, 9 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 3,6,9,and 12 abstinence of gambling will be assessed.
|
Baseline to Week 3, 6, 9 and 12
|
Internet use (Internet disorder scale-9 short form)
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 6, and 12 internet use will be assessed.
|
Baseline to Week 6 and 12
|
Quality of life (WHO: EUROHIS-8)
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 6, and 12 quality of life will be assessed.
|
Baseline to Week 6 and 12
|
Alcohol consumption (AUDIT)
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 6, and 12 graving of gambling will be assessed.
|
Baseline to Week 6 and 12
|
Depression (MADRS)
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
From baseline to weeks 6, and 12 mood will be assessed.
|
Baseline to Week 6 and 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and proportion of subjects with adverse events
Time Frame: Baseline to week 12 - daily
|
The use of the daily questionnaire / telephone operated (text messages) diary (daily use of sprays, number of doses, gambling expenditure and frequency and possible adverse events) and self-administration of IMP.
|
Baseline to week 12 - daily
|
Assessment of clinical laboratory parameters - Pregnancy test
Time Frame: Screening to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
At Screening and week 12 blood pregnancy test and week 6 urine pregnancy test
|
Screening to Week 6 and 12
|
Assessment of vital signs - blood pressure, pulse, temperature
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
Assessments at baseline, 6 and 12 vital signs ( blood pressure, pulse and temperature) will be assessed.
|
Baseline to Week 6 and 12
|
Assessment of body height
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
Assessments at the baseline, week 6, and week 12. Body height will be assessed.
|
Baseline to Week 6 and 12
|
Assessment of body weight
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
Assessment at baseline, 6, and 12 .
Body weight will be assessed.
|
Baseline to Week 6 and 12
|
Assessment and examination of nasal mucosa
Time Frame: Baseline to Week 6 and 12
|
The entire study for an individual participant will last 12 weeks.
Assessment at baseline, 6, and 12 nasal mucosa will be assessed using Nasal Irritation Scale (0= normal appearing mucosa, no bleeding to 5= Ulcerated lesions, bleeding with requires medical intervention).
Assessment is performed by MD.
|
Baseline to Week 6 and 12
|
Assessment of smell test
Time Frame: Baseline to Week 12
|
The entire study for an individual participant will last 12 weeks.
Assessments at baseline and week 12 smell will be assessed.Smell test will be conducted at Baseline and Week 12. NIH Toolbox Odour Identification Test: This validated smell identification test uses 'scratch and sniff' technology, and pictures for the multiple-choice options of 9 common smells.
It is intended for a rapid research assessment of olfactory ability.
|
Baseline to Week 12
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hannu Alho, Prof., Finnish Institute for Health and Welfare
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NalGamb
- 2017-001946-93 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Naloxone
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA)Completed
-
University of Alabama at BirminghamCompleted
-
Finnish Institute for Health and WelfareCompletedNaloxone | Gambling | Spray | OpioidFinland
-
Rigshospitalet, DenmarkCompletedPain | Naloxone | Hyperalgesia | Opioid AntagonistDenmark
-
Indivior Inc.CompletedNaloxone | Drug Abuse | Opiate Dependence | Buprenorphine | Opiate-related Disorders
-
State University of New York - Upstate Medical...Binghamton UniversityCompletedHarm Reduction | Opioid-use Disorder | NaloxoneUnited States
-
University Hospital Inselspital, BerneCompletedEpidural Analgesia | Radical Cystectomy | Postoperative Pain Management | Oral Oxycodone With/Without Naloxone | Return of the Bowel FunctionSwitzerland
-
University of California, San FranciscoNot yet recruitingHeart Arrest, Out-Of-Hospital | Naloxone | Opioid OverdoseUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States